Dupixent vs. Fasenra

Dupixent (dupilumab) injection and Fasenra (benralizumab) injection are monoclonal antibodies used to treat asthma.

Dupixent is also used to treat adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

Side effects of Dupixent and Fasenra that are similar include injection site reactions (pain, redness, itching, or a small lump).

Side effects of Dupixent that are different from Fasenra include pink eye (conjunctivitis), swollen or puffy eyelids, oral herpes, inflammation of the cornea (keratitis), eye itching, other herpes simplex virus infection, and dry eye.

Side effects of Fasenra that are different from Dupixent include headache, sore throat, fever, and hypersensitivity reactions.

Dupixent may interact with "live" vaccines, warfarin, and cyclosporine.

Fasenra may interact with other drugs.

Common side effects of Dupixent include:

• injection site reactions,
• pink eye (conjunctivitis),
• swollen or puffy eyelids,
• oral herpes,
• inflammation of the cornea (keratitis),
• eye itching,
• other herpes simplex virus infection, and
• dry eye.

Common side effects of Fasenra include:

• headache,
• sore throat,
• fever,
• hypersensitivity reactions, and
• injection site reactions (pain, redness, itching, or a small lump)

Dupixent (dupilumab) injection is aninterleukin-4 receptor alpha-antagonist indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

Fasenra (benralizumab) injection is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Dupixent may interact with:

• "live" vaccines
• ,
• warfarin, or
• cyclosporine

Fasenra may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Fasenra; it is unknown how it would affect a fetus. Monoclonal antibodies such as Fasenra are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy. It is unknown if Fasenra passes into breast milk or how it would affect a nursing infant. Consult your doctor before breastfeeding.

The recommended dose of Dupixent is an initial dose of 600 mg (two 300 mg injections in different injection sites), followed by 300 mg given every other week.

The dose of Fasenra is one tablet taken orally once daily with or without food.